Sign In
Buy IDNA
$28.89
+0.210 (+0.732%)
At Close: Jun 03, 2026
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Up 428.3% in January
02:46am, Wednesday, 28'th Jan 2026
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short int
Flow Traders U.S. LLC Buys Shares of 45,404 iShares Genomics Immunology and Healthcare ETF $IDNA
04:26am, Wednesday, 10'th Dec 2025
Flow Traders U.S. LLC purchased a new position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the undefined quarter, according to the company in its most recent disclos
IDNA: The Cutting Edge Of Medical Science Is A Risky Investment
11:28am, Sunday, 20'th Apr 2025
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value charac
Disruptive Theme of the Week – Breakthroughs in Medicine
03:35pm, Thursday, 21'st Nov 2024
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakth
IDNA: Healthcare Dashboard For February
06:39am, Sunday, 18'th Feb 2024
This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheap
Disruptive Tech Theme of the Week: 7 Disruptive Themes for 2024
11:51am, Monday, 18'th Dec 2023
To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.
VettaFi Voices On: Accessing Disruptive Innovation
04:04pm, Friday, 17'th Nov 2023
Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.
IDNA: Continues To Underperform, But With Long-Term Potential
04:03am, Thursday, 08'th Jun 2023
I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experien
IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run
12:34pm, Wednesday, 07'th Jun 2023
Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to en
Thematic Index Lineup Joins VettaFi and the Future Is Bright
10:01am, Monday, 10'th Apr 2023
A decade ago, when the ROBO Global Robotics & Automation Index ETF (ROBO) launched, the U.S. thematic ETF market was nascent, with only a handful of products and minimal assets. However, at the end of
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
11:31am, Wednesday, 15'th Mar 2023
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
IDNA: Healthcare Dashboard For February
03:45pm, Thursday, 16'th Feb 2023
Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality.
Will 2023 be the Year of Cathie Wood ETFs?
09:02am, Tuesday, 24'th Jan 2023
Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.
Can Health Care Stocks Outperform Again In 2023?
06:09pm, Wednesday, 11'th Jan 2023
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
IDNA: Healthcare Dashboard For November
12:26pm, Wednesday, 16'th Nov 2022
The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metr
